Goswami, Sangeeta

Immune checkpoint therapy—current perspectives and future directions

Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,206

The Next Decade of Immune Checkpoint Therapy

Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 750

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

Goswami, S., Walle, T., Cornish, A. E., Basu, S., Anandhan, S., Fernandez, I., Vence, L., Blando, J., Zhao, H., Yadav, S. S., et al. (2020) · Nature Medicine

Cancer Immunotherapy and BiomarkersGlioma Diagnosis and Treatment

Cited by 356

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 318

Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy

Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., et al. (2018) · Journal of Clinical Investigation

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 244

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC

Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., et al. (2020) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 133

Belzutifan efficacy and tolerability in patients with sporadic metastatic clear cell renal cell carcinoma

Wang, E., Rupe, E. S., Mukhida, S. S., Johns, A. C., Campbell, M. T., Shah, A. Y., Zurita, A. J., Gao, J., Goswami, S., Jonasch, E., et al. (2025) · European Urology Focus

Renal cell carcinoma treatmentFerroptosis and cancer prognosis

Cited by 4